CN102188476A - Composition of effective Chinese medicine components for treating hepatic fibrosis - Google Patents
Composition of effective Chinese medicine components for treating hepatic fibrosis Download PDFInfo
- Publication number
- CN102188476A CN102188476A CN 201110111291 CN201110111291A CN102188476A CN 102188476 A CN102188476 A CN 102188476A CN 201110111291 CN201110111291 CN 201110111291 CN 201110111291 A CN201110111291 A CN 201110111291A CN 102188476 A CN102188476 A CN 102188476A
- Authority
- CN
- China
- Prior art keywords
- hepatic fibrosis
- chinese medicine
- composition
- active ingredient
- effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition of effective Chinese medicine components for treating hepatic fibrosis, which is prepared from the following effective components of crude medicine in parts by weight: 10-30 parts of gentiana veitchiorum and 10-30 parts of pseudo-ginseng, wherein effective components of the gentiana veitchiorum include gentiamarin, loganic acid, homo-orientin-3-methyl ether, neovitexin and homo-orientin, and the effective component of the pseudo-ginseng is Panax notoginseng saponin. The raw materials of the composition of the effective Chinese medicine components are easy to obtain, and the cost of the composition is low. The composition of the effective Chinese medicine components can be used for eliminating inflammatory cells and inflammatory media of hepatic phlogosis and resisting hepatic fibrosis caused by hepatitis virus infection, has characteristics of safety, low toxicity and favorable curative effect, and has special curative effects to secondary or idiopathic hepatic fibrosis caused by the hepatitis virus infection; in addition, the curative effects of the composition are better than the curative effects of only using hormone, therefore, adverse effects of inflammation diffusion, femoral head necrosis and the like caused by the long-term application of large amount of hormone are avoided.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of Chinese medicine active ingredient composition for the treatment of hepatic fibrosis.
Background technology
Hepatic fibrosis is that many chronic paathogenic factors act on liver and cause ECM (extra cellular matrix, extracellular matrix) the common pathological process of over-deposit, virulence factor cause that liver response to oxidative stress and production of cytokines are the initiating links that hepatic fibrosis takes place.Ucleosides antiviral agents Lamivudine (lamivudine) prolonged application can be improved the inflammation of liver, and can alleviate or stop the progress of hepatic fibrosis; Retinoic acid can suppress HSC (hepatic stellate cell) procollagen I, II, IV, fiber adhesion albumen, mucinous synthetic and promotion mononuclear cell secretion collagenase, suppress the activation of HSC, and activatory HSC is reversed to resting state, ECM (extracellular matrix) is synthetic to be reduced thereby make, yet life-time service has toxic action to liver.Multiple medicine all has certain effect to the treatment of hepatic fibrosis, as IFN-γ, though observe the effect of fibrosis preferably, to the side effects limit of body its use, high expense also makes general income person hang back simultaneously.
The traditional Chinese medical science thinks that " hot and humid ecchymosis " causes chronic hepatic injury, and " hot and humid ecchymosis " also is the initiating agent of hepatic fibrosis, is the pathogenesis that continues.The evil stasis of blood of the damp and hot poison liver network blood system that stagnates, the liver network is injured, and malicious heresy causes the stasis of blood, and blood stasis is not changed and is helped humidogene heat, " hot and humid ecchymosis " to amass in the liver network, just the hepatic fibrosis principal element that forms and increase the weight of.Hot and humid ecchymosis continue to exist, and damage healthy energy causes deficiency-weakness of spleen-QI, hepatic and renal YIN deficiency, deficiency of spleen-YANG and kidneyYANG then, final form gather, the card of refractory such as tympanites.The pathogenesis evolution process of chronic hepatopathy (the cloudy loss of damp and hot-blood stasis-stagnant heat-hot and humid ecchymosis-gas) is the important step that hepatic fibrosis forms and increases the weight of, and wherein hot and humid ecchymosis is the most key." Ling Shu Miraculous Pivot or Divine Axis. all kinds of diseases and ailments beginnings is given birth to a piece of writing " think that pathogenic factor is invaded human body, internal injury melancholy anger, or daily life in addition such as does not save at reason, cause " dampness is not all right, and in blood coagulation is accumulate and do not loose, body fluid is puckery to be oozed, work and not going, and long-pendingly all become ".Invade liver as exopathogen such as " epidemic disease caused by damp-heat pathogen poison ", " diseasess due to noxious agents produced by various parasites ", or food and drink is hindered, prolongedly do not heal, gradually to functional disorders such as liver,spleen,kidneys, gas, blood, the rich joint of body fluid, it is stagnant obstructed to make passages through which vital energy circulates stop up, so that yang-energy can not pass unimpeded, and causes that blood clotting can not dissipate in the lining, the infusion of body fluid also takes place not smooth, cause phlegm-damp, congestion deposition eventually, the liver network becomes silted up and hinders into disease.Therefore, " blood coagulation accumulate in ", " body fluid is puckery to be oozed " are the total pathogenesis that forms hepatic fibrosis.
The traditional Chinese medical science is many to the treatment of hepatic fibrosis to be auxilliary based on blood circulation promoting and blood stasis dispelling, supplementing QI and nourishing YIN.But current differentiation of symptoms and signs for classification of syndrome to hepatic fibrosis is respectively held and is seen, does not still have unified, normalized standard, and each card is usually held concurrently mutually.We think the method for clinical employing " differential diagnosis of diseases is in conjunction with dialectical ", can receive better therapeutic.Look after on the one hand the general character of primary disease, i.e. liver blood stasis of blood resistance, deficiency of vital QI, and select for use Chinese medicine to make patent medicine in conjunction with the modern pharmacological research achievement, to anti-hepatic fibrosis, make things convenient for patient's medication with effectively simultaneously; On the other hand can be according to the individual character of different patient's cold and heat and asthenia and sthenias, the difference of assorted card of holding concurrently, plus-minus uses decoction on dialectical basis, to improve curative effect.The Chinese patent medicine preparation of treatment hepatic fibrosis, as compound recipe 861, medical materials such as the Cordyceps in two first five curing capsule prescriptions, Carapax Trionycis, Squama Manis are famous and precious, rare, cost an arm and a leg.
Summary of the invention
Technical problem to be solved by this invention is at above-mentioned deficiency of the prior art, a kind of safety is provided, low toxicity, the Chinese medicine active ingredient composition of treatment hepatic fibrosis evident in efficacy, said composition can be removed the inflammatory cell and the inflammatory mediator of liver's inflammation, and is particularly evident in efficacy to the hepatic fibrosis that hepatites virus infections causes.
For solving the problems of the technologies described above, the technical solution used in the present invention is: a kind of Chinese medicine active ingredient composition for the treatment of hepatic fibrosis is characterized in that said composition is formulated by following weight portion raw material the effective elements of the medicine:
10～30 parts of 10～30 portions of Radix Notoginseng of Gentiana veitchiorum;
The effective ingredient of described Gentiana veitchiorum is a gentiopicrin, the dry acid that falls, isorientin-3-methyl ether, Saponaretin and isorientin, and the effective ingredient of described Radix Notoginseng is a Radix Notoginseng total arasaponins.
Above-mentioned a kind of Chinese medicine active ingredient composition for the treatment of hepatic fibrosis, the dosage form of described Chinese medicine active ingredient composition is oral formulations or injection.
Above-mentioned a kind of Chinese medicine active ingredient composition for the treatment of hepatic fibrosis, described oral formulations is capsule, soft capsule, tablet, oral solutions, honey pill agent, water droplet pill, unguentum, powder or electuary.
Above-mentioned a kind of Chinese medicine active ingredient composition for the treatment of hepatic fibrosis, described hepatic fibrosis is fibrosis in chronic liver disease or viral hepatic fibrosis.
Above-mentioned a kind of Chinese medicine active ingredient composition for the treatment of hepatic fibrosis, described viral hepatic fibrosis are by Secondary cases due to the hepatites virus infections or the hepatic fibrosis of the special property sent out.
Described weight portion can be weight metering units such as gram, two, jin, kilogram, ton.
The preparation technology of injection of the present invention: the method for above-mentioned effective ingredient being made routinely injection is made injection, and every injection contains crude drug 3g～5g.
The capsular preparation technology of the present invention: above-mentioned effective ingredient is made capsular method routinely make capsule, carrier is conventional pharmaceutical carrier, and every capsules contains crude drug 3g～5g.
Preparation of soft capsule technology of the present invention: the method for above-mentioned effective ingredient being made routinely soft capsule is made soft capsule, and carrier is conventional pharmaceutical carrier, and every soft capsule contains crude drug 3g～5g.
The preparation technology of tablet of the present invention: with above-mentioned effective ingredient routinely the method for film-making agent make tablet, adjuvant is conventional pharmaceutic adjuvant, every contains crude drug 3g～5g.
The preparation technology of oral liquid of the present invention: the method for above-mentioned effective ingredient being made routinely oral liquid is made oral liquid with flavoring agent, every bottle of 20mL, and every bottle contains crude drug 3g～5g.
The preparation technology of honeyed pill of the present invention: the method for above-mentioned effective ingredient being made routinely honeyed pill is made honeyed pill, and every ball contains crude drug 3g～5g.
The preparation technology of water droplet ball of the present invention: with above-mentioned effective ingredient routinely the method for controlling the water circulation drop pill make the water droplet ball, the packing, every bottle 20 ball, every bottle contains crude drug 3g～5g.
The preparation technology of unguentum of the present invention: above-mentioned effective ingredient is dissolved in water, is concentrated into clear paste, the method for making unguentum then routinely adds the close or Nulomoline of refining, the slow fire heating, and fill obtains unguentum behind the mix homogeneously.
The preparation technology of powder of the present invention: the method for above-mentioned effective ingredient being made routinely powder is made powder, every packed crude drug 3g～5g.
The preparation technology of electuary of the present invention: the method for above-mentioned effective ingredient being made routinely electuary is made electuary, every packed crude drug 3g～5g.
Gentiana veitchiorum grows in height above sea level more than 4000 meters, high and cold anoxia, sunshine is strong, the temperature difference is greatly different, dry, free of contamination region.The Tibetan medicine Gentiana veitchiorum has heat-clearing and toxic substances removing, and the dampness removing effect cures mainly the liver-heat cough, headache conjunctival congestion, laryngopharynx swelling and pain, jaundice due to damp-heat, stranguria with turbid discharge.But the Tibetan medicine Gentiana veitchiorum was not seen project verification on the version in 2010 at Pharmacopoeia of People's Republic of China, did not see its effective medicinal components.
Extracting solution after the present invention adopts high pressure liquid chromatograph to Gentiana veitchiorum decoction extraction or soak with ethanol extraction detects, the effective ingredient of finding Gentiana veitchiorum also contains to fall dry acid, isorientin-3-methyl ether, Saponaretin and isorientin except that gentiopicrin.
Its decline dry acid is present in Tibetan medicine gentiana straminea maxim, Herba Haleniae Corniculatae, Radix Gentianae and Herba Swertiae bimaculatae etc., and the gentiana straminea maxim root is used for the treatment of diseases such as rheumatic arthritis, pneumonopathy fever, jaundice, erythra, edema and constipation and anuresis for top grade Tibetan medicine commonly used; Herba Haleniae Corniculatae is used for the treatment of infantile acute jaundice and infantile acute hepatitis B has been obtained better curative effect; Radix Gentianae and Herba Swertiae bimaculatae are mainly used in the acute and chronic hepatitis of treatment, fatty liver, liver cirrhosis, acute and chronic cholecystitis, cholelithiasis, anemia etc. clinically, and has tonic effect, do not see that at present above medical material is not seen relevant pharmacological experiment study yet to the fall pharmaceutical research of dry acid of this composition monomer.
Isorientin-3-methyl ether chemistry structure is as follows, does not find at present and contains this chemical compound in the other drug.
Saponaretin belongs to flavone compound, all contains this composition in Chinese medicine Folium Bambusae, Semen Cajani, patrima villosa grass, the little Folium fici microcarpae, there are some researches show that the flavone in the Folium Bambusae has immunization of cell; The effect of patrima villosa medical herbs reason mainly concentrates on antitumor and anoxia enduring, but not mentioned effective ingredient is a flavonoid; Do not see at present pharmaceutical research to this composition monomer Saponaretin.
The isorientin chemical constitution is as follows, does not see at present the monomeric pharmaceutical research of this composition.
The component analysis of Radix Notoginseng is known for everyone, and its effective ingredient Radix Notoginseng total arasaponins main pharmacological has: 1, blood vessel dilating, bring high blood pressure down microcirculation improvement, blood flow increasing, prevention and treatment heart and brain tissues ischemia, anoxia; 2, promote protein, ribonucleic acid (RNA), DNA (deoxyribonucleic acid) (DNA) to synthesize building body; 3, promote blood cell metabolism, balance adjustment blood cell; 4, two-ways regulation nervus centralis improves mentality, strengthens the learning and memory ability; 5, enhancing human body immunity function, antitumor; 6, hemostasis, blood circulation promoting and blood stasis dispelling; 7, fibrosis activity; 8, slow down aging; 9, two-ways regulation blood glucose, blood fat reducing, cholesterol, inhibition arteriosclerosis.
The present invention is in line with the Therapeutic Principle of the collaborative antiinflammatory of the effective ingredient in Radix Notoginseng total arasaponins and the Gentiana veitchiorum, collaborative anti-hepatic fibrosis, reasonable compatibility, can remove the inflammatory cell and the inflammatory mediator of liver's inflammation, the hepatic fibrosis that the antagonism hepatites virus infections causes, has safety, low toxicity, characteristics evident in efficacy.
The present invention compared with prior art has the following advantages:
1, the present invention confirms in the treatment pharmacodynamic experiment of the inductive hepatic fibrosis of rat N-nitrosodimethylamine, Chinese medicine active ingredient composition of the present invention has special curative effect to acute and chronic inflammation with by Secondary cases due to the hepatites virus infections or the hepatic fibrosis of the special property sent out, its curative effect is better than using merely hormone, can avoid ill effects such as long-term, heavy dose of use inflammation diffusion that hormone caused, sequestrum disease.
2, Chinese medicine active ingredient composition of the present invention utilizes the collaborative antiinflammatory of effective ingredient in Radix Notoginseng total arasaponins and the Gentiana veitchiorum, the Therapeutic Principle of collaborative anti-hepatic fibrosis, reasonable compatibility, can remove the inflammatory cell and the inflammatory mediator of liver's inflammation, the hepatic fibrosis that the antagonism hepatites virus infections causes, has safety, low toxicity, characteristics evident in efficacy.
3, Chinese medicine active ingredient composition raw material of the present invention is easy to get, and price is lower, is fit to promote the use of.
Description of drawings
Fig. 1 is each group rat liver tissue slice MASSON coloration result (microscope amplification 4 * 10).
Fig. 2 is each group rat liver tissue slice HE coloration result (microscope amplification 4 * 10).
The specific embodiment
Embodiment 1
The Chinese medicine active ingredient composition of present embodiment is formulated by following weight portion raw material the effective elements of the medicine: Gentiana veitchiorum 20g, Radix Notoginseng 30g; Wherein the effective ingredient of Gentiana veitchiorum be gentiopicrin, the dry acid that falls, isorientin-3-methyl ether, Saponaretin and isorientin, the effective ingredient of described Radix Notoginseng is a Radix Notoginseng total arasaponins.
Its preparation method is: the method for above-mentioned effective ingredient being made routinely injection is made injection, and every injection contains crude drug 3g～5g.
Embodiment 2
The Chinese medicine active ingredient composition of present embodiment is formulated by following weight portion raw material the effective elements of the medicine: Gentiana veitchiorum 10g, Radix Notoginseng 30g; Wherein the effective ingredient of Gentiana veitchiorum be gentiopicrin, the dry acid that falls, isorientin-3-methyl ether, Saponaretin and isorientin, the effective ingredient of described Radix Notoginseng is a Radix Notoginseng total arasaponins.
Its preparation method is: above-mentioned effective ingredient is made capsular method routinely make capsule, carrier is conventional pharmaceutical carrier, and every capsules contains crude drug 3g～5g.
Embodiment 3
The Chinese medicine active ingredient composition of present embodiment is formulated by following weight portion raw material the effective elements of the medicine: Gentiana veitchiorum 20g, Radix Notoginseng 10g; Wherein the effective ingredient of Gentiana veitchiorum be gentiopicrin, the dry acid that falls, isorientin-3-methyl ether, Saponaretin and isorientin, the effective ingredient of described Radix Notoginseng is a Radix Notoginseng total arasaponins.
Its preparation method is: the method for above-mentioned effective ingredient being made routinely soft capsule is made soft capsule, and carrier is conventional pharmaceutical carrier, and every soft capsule contains crude drug 3g～5g.
Embodiment 4
The Chinese medicine active ingredient composition of present embodiment is formulated by following weight portion raw material the effective elements of the medicine: Gentiana veitchiorum 30g, Radix Notoginseng 20g; Wherein the effective ingredient of Gentiana veitchiorum be gentiopicrin, the dry acid that falls, isorientin-3-methyl ether, Saponaretin and isorientin, the effective ingredient of described Radix Notoginseng is a Radix Notoginseng total arasaponins.
Its preparation method is: with above-mentioned effective ingredient routinely the method for film-making agent make tablet, adjuvant is conventional pharmaceutic adjuvant, every contains crude drug 3g～5g.
Embodiment 5
The Chinese medicine active ingredient composition of present embodiment is formulated by following weight portion raw material the effective elements of the medicine: Gentiana veitchiorum 10g, Radix Notoginseng 10g; Wherein the effective ingredient of Gentiana veitchiorum be gentiopicrin, the dry acid that falls, isorientin-3-methyl ether, Saponaretin and isorientin, the effective ingredient of described Radix Notoginseng is a Radix Notoginseng total arasaponins.
Its preparation method is: the method for above-mentioned effective ingredient being made routinely oral liquid is made oral liquid with flavoring agent, every bottle of 20mL, and every bottle contains crude drug 3g～5g.
Embodiment 6
The Chinese medicine active ingredient composition of present embodiment is formulated by following weight portion raw material the effective elements of the medicine: Gentiana veitchiorum 30g, Radix Notoginseng 20g; Wherein the effective ingredient of Gentiana veitchiorum be gentiopicrin, the dry acid that falls, isorientin-3-methyl ether, Saponaretin and isorientin, the effective ingredient of described Radix Notoginseng is a Radix Notoginseng total arasaponins.
Its preparation method is: the method for above-mentioned effective ingredient being made routinely honeyed pill is made honeyed pill, and every ball contains crude drug 3g～5g.
Embodiment 7
The Chinese medicine active ingredient composition of present embodiment is formulated by following weight portion raw material the effective elements of the medicine: Gentiana veitchiorum 20g, Radix Notoginseng 20g; Wherein the effective ingredient of Gentiana veitchiorum be gentiopicrin, the dry acid that falls, isorientin-3-methyl ether, Saponaretin and isorientin, the effective ingredient of described Radix Notoginseng is a Radix Notoginseng total arasaponins.
Its preparation method is: with above-mentioned effective ingredient routinely the method for controlling the water circulation drop pill make the water droplet ball, the packing, every bottle 20 ball, every bottle contains crude drug 3g～5g.
Embodiment 8
The Chinese medicine active ingredient composition of present embodiment is formulated by following weight portion raw material the effective elements of the medicine: Gentiana veitchiorum 30g, Radix Notoginseng 10g; Wherein the effective ingredient of Gentiana veitchiorum be gentiopicrin, the dry acid that falls, isorientin-3-methyl ether, Saponaretin and isorientin, the effective ingredient of described Radix Notoginseng is a Radix Notoginseng total arasaponins.
Its preparation method is: above-mentioned effective ingredient is dissolved in water, is concentrated into clear paste, the method for making unguentum then routinely adds the close or Nulomoline of refining, the slow fire heating, and fill obtains unguentum behind the mix homogeneously.
Embodiment 9
The Chinese medicine active ingredient composition of present embodiment is formulated by following weight portion raw material the effective elements of the medicine: Gentiana veitchiorum 30g, Radix Notoginseng 30g; Wherein the effective ingredient of Gentiana veitchiorum be gentiopicrin, the dry acid that falls, isorientin-3-methyl ether, Saponaretin and isorientin, the effective ingredient of described Radix Notoginseng is a Radix Notoginseng total arasaponins.
Its preparation method is: the method for above-mentioned effective ingredient being made routinely powder is made powder, every packed crude drug 3g～5g.
Embodiment 10
The Chinese medicine active ingredient composition of present embodiment is formulated by following weight portion raw material the effective elements of the medicine: Gentiana veitchiorum 10g, Radix Notoginseng 20g; Wherein the effective ingredient of Gentiana veitchiorum be gentiopicrin, the dry acid that falls, isorientin-3-methyl ether, Saponaretin and isorientin, the effective ingredient of described Radix Notoginseng is a Radix Notoginseng total arasaponins.
Its preparation method is: the method for above-mentioned effective ingredient being made routinely electuary is made electuary, every packed crude drug 3g～5g.
The present invention makes Liver Fibrosis Model with N-nitrosodimethylamine (DMN) lumbar injection, DMN model and carbon tetrachloride (CCl
4), Liver Fibrosis Model difference such as galactosamine, its pathological changes has progressivity, is difficult for spontaneous recovery in a short time, is the best model of observing the anti-hepatic fibrosis medicines therapeutic effect.Therefore adopt the method for DMN lumbar injection to prepare the DMN Liver Fibrosis Model, to observe the curative effect of Chinese medicine active ingredient composition control hepatic fibrosis of the present invention.
41 rats are divided into six groups, 6 of normal control groups (not accepting the DMN lumbar injection); DMN organizes (not receiving treatment behind the DMN lumbar injection) 6; Totally 23 of Chinese medicine active ingredient composition treatment groups of the present invention, wherein KL (accepting Chinese medicine active ingredient composition treatment of the present invention one month behind the DMN lumbar injection) low dosage (1g crude drug/kg body weight/day) group is 7, dosage (2g crude drug/kg body weight/day) group is 8 among the KL (accepting Chinese medicine active ingredient composition treatment of the present invention one month behind the DMN lumbar injection), 8 of KL (accepting Chinese medicine active ingredient composition treatment of the present invention one month behind the DMN lumbar injection) high dose (4g crude drug/kg body weight/day) groups; 6 of positive control drug groups-prednisone group (the prednisone sheet of accepting routine dose behind the DMN lumbar injection was treated month), each organizes degree of hepatic fibrosis such as following table:
Table 1 is respectively organized degree of hepatic fibrosis relatively
A: compare P＜0.05 with the DMN group; B: compare P＜0.05 with the normal control group.
DMN treated animal liver is seriously damaged, fibrosis in various degree all appears in animal, collagen fiber are distributed in portal area and central vein tube wall and the incomplete fibrous septum in a large number, form tangible pseudolobuli, and in the Chinese medicine active ingredient composition treatment group of the present invention, though can also see the collagen hypertrophy, but degree significantly alleviates than the DMN group, do not form tangible pseudolobuli, the leaching of inflammatory cell also reduces to some extent, and alleviating with amount of drug of fibrosis is directly proportional.
After testing, it is as shown in the table that each organizes the variation of ALT in the rat blood serum (glutamate pyruvate transaminase) and HA (hyaluronic acid):
Table 2 is respectively organized the variation of ALT and HA in the rat blood serum
A: compare P＜0.05 with the DMN group; B: compare P＜0.05 with the normal control group.
Chinese medicine active ingredient composition of the present invention can significantly reduce the ALT content in the inductive hepatic fibrosis rats serum of DMN, and is obvious than control drug prednisone group effect, illustrates that this Chinese medicine active ingredient composition has the liver protecting, improves the effect of liver function; Can prevent and significantly alleviate the formation of hepatic fibrosis, this Chinese medicine active ingredient composition high dose prednisone that is better than evident in efficacy.
After testing, it is as shown in the table that each organizes the variation of SOD in the liver tissues of rats homogenate (superoxide dismutase), GSH (glutathion), MAO (monoamine oxidase, MAO), MDA (malonaldehyde) content:
Table 3 is respectively organized the variation of SOD, GSH in the liver tissues of rats homogenate, MAO, MDA content
A: compare P＜0.05 with the DMN group; B: compare P＜0.05 with the normal control group;
DMN group SOD, GSH vigor all are markedly inferior to normal control group (P＜0.05), and the MAO vigor is higher than the normal control group significantly, and MDA also is higher than the normal control group, but does not have marked difference; KL high dose group SOD, GSH vigor are higher than DMN group (P＜0.05) significantly, normal matched group does not have marked difference, the MAO vigor is markedly inferior to DMN group (P＜0.05), there is not significant difference with the normal control group, the MDA vigor is markedly inferior to DMN group (P＜0.05), also significantly is lower than the normal control group; Prednisone group SOD, GSH vigor significantly are lower than the normal control group, do not have significant difference, MAO, MDA vigor to be markedly inferior to DMN group (P＜0.05) with the DMN group, and wherein the MDA vigor also significantly is lower than the normal control group.
The pathology section examination of tissue is the most direct foundation of diagnosis, therefore the applicant carries out sections observation to the liver organization of each group rat, the result as depicted in figs. 1 and 2, DMN treated animal liver is seriously damaged, collagen fiber are distributed in portal area and central vein tube wall and the incomplete fibrous septum in a large number, form tangible pseudolobuli, and in the Chinese medicine active ingredient composition treatment group of the present invention, though can also see the collagen hypertrophy, but degree significantly alleviates than the DMN group, do not form tangible pseudolobuli, the leaching of inflammatory cell also reduces to some extent.Its clinical commonly used drug prednisone that is better than evident in efficacy.
Chinese medicine active ingredient composition of the present invention utilizes the Therapeutic Principle of the collaborative antiinflammatory of the effective ingredient in Radix Notoginseng total arasaponins and the Gentiana veitchiorum, collaborative anti-hepatic fibrosis, reasonable compatibility, in the treatment pharmacodynamic experiment of the inductive hepatic fibrosis of rat N-nitrosodimethylamine, confirm, this Chinese medicine active ingredient composition has special curative effect to acute and chronic inflammation with by Secondary cases due to the hepatites virus infections or the hepatic fibrosis of the special property sent out, its curative effect is better than using merely hormone, can avoid ill effects such as long-term, heavy dose of use inflammation diffusion that hormone caused, sequestrum disease.Chinese medicine active ingredient composition raw material of the present invention is easy to get, and price is lower, can remove the inflammatory cell and the inflammatory mediator of liver's inflammation, and the hepatic fibrosis that the antagonism hepatites virus infections causes has safety, low toxicity, and characteristics evident in efficacy are fit to promote the use of.
The above; it only is preferred embodiment of the present invention; be not that the present invention is done any restriction, everyly any simple modification that above embodiment did, change and equivalent structure changed, all still belong in the protection domain of technical solution of the present invention according to the invention technical spirit.
Claims (5)
1. a Chinese medicine active ingredient composition for the treatment of hepatic fibrosis is characterized in that, said composition is formulated by following weight portion raw material the effective elements of the medicine:
10～30 parts of 10～30 portions of Radix Notoginseng of Gentiana veitchiorum;
The effective ingredient of described Gentiana veitchiorum is a gentiopicrin, the dry acid that falls, isorientin-3-methyl ether, Saponaretin and isorientin, and the effective ingredient of described Radix Notoginseng is a Radix Notoginseng total arasaponins.
2. a kind of Chinese medicine active ingredient composition for the treatment of hepatic fibrosis according to claim 1 is characterized in that the dosage form of described Chinese medicine active ingredient composition is oral formulations or injection.
3. a kind of Chinese medicine active ingredient composition for the treatment of hepatic fibrosis according to claim 2 is characterized in that described oral formulations is capsule, soft capsule, tablet, oral solutions, honey pill agent, water droplet pill, unguentum, powder or electuary.
4. a kind of Chinese medicine active ingredient composition for the treatment of hepatic fibrosis according to claim 1 is characterized in that described hepatic fibrosis is fibrosis in chronic liver disease or viral hepatic fibrosis.
5. a kind of Chinese medicine active ingredient composition for the treatment of hepatic fibrosis according to claim 4 is characterized in that, described viral hepatic fibrosis is by Secondary cases due to the hepatites virus infections or the hepatic fibrosis of the special property sent out.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110111291 CN102188476B (en) | 2011-04-29 | 2011-04-29 | Composition of effective Chinese medicine components for treating hepatic fibrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110111291 CN102188476B (en) | 2011-04-29 | 2011-04-29 | Composition of effective Chinese medicine components for treating hepatic fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102188476A true CN102188476A (en) | 2011-09-21 |
| CN102188476B CN102188476B (en) | 2013-03-06 |
Family
ID=44597911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110111291 Active CN102188476B (en) | 2011-04-29 | 2011-04-29 | Composition of effective Chinese medicine components for treating hepatic fibrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102188476B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105616434A (en) * | 2016-02-17 | 2016-06-01 | 黄权芳 | Application of isoorientin of babysbreath to preparing medicines for treating immunological hepatic fibrosis |
| CN105726528A (en) * | 2016-02-17 | 2016-07-06 | 黄权芳 | Application of babybreath isoorientin to preparation of medicine for treating chemical hepatic fibrosis |
| CN107669625A (en) * | 2017-09-29 | 2018-02-09 | 昆明医科大学 | Anti-fibrosis drug, preparation method, application and animal model constructing method |
| CN108535368A (en) * | 2018-03-13 | 2018-09-14 | 宇妥藏药股份有限公司 | A kind of method of quality control of three tastes rough gentian flower piece |
-
2011
- 2011-04-29 CN CN 201110111291 patent/CN102188476B/en active Active
Non-Patent Citations (5)
| Title |
|---|
| 《世界华人消化杂志》 20090108 房志鑫等 蓝玉簪颗粒对大鼠肝纤维化的治疗作用 11-16 1-5 第17卷, 第1期 * |
| 《中国中药杂志》 20081130 杨红澎 蓝玉簪龙胆中苷类成分的研究 2505-2507 1-5 第33卷, 第21期 * |
| 《中国优秀硕士学位论文全文数据库第四军医大学硕士学位论文》 20081205 李鹏 蓝玉簪颗粒对肝纤维化的治疗作用研究 1-79 1-5 , * |
| 《中国药师》 20100831 李旭波等 蓝玉簪颗粒抗肝纤维化的作用研究 1069-1071 1-5 第13卷, 第8期 * |
| 《华西药学杂志》 20101031 邹琼宇等 蓝玉簪龙胆的化学成分研究 512-514 1-5 第25卷, 第5期 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105616434A (en) * | 2016-02-17 | 2016-06-01 | 黄权芳 | Application of isoorientin of babysbreath to preparing medicines for treating immunological hepatic fibrosis |
| CN105726528A (en) * | 2016-02-17 | 2016-07-06 | 黄权芳 | Application of babybreath isoorientin to preparation of medicine for treating chemical hepatic fibrosis |
| CN107669625A (en) * | 2017-09-29 | 2018-02-09 | 昆明医科大学 | Anti-fibrosis drug, preparation method, application and animal model constructing method |
| CN108535368A (en) * | 2018-03-13 | 2018-09-14 | 宇妥藏药股份有限公司 | A kind of method of quality control of three tastes rough gentian flower piece |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102188476B (en) | 2013-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101357219B (en) | Medicine for treating chronic hepatitis B | |
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN102188513A (en) | Medical composition with auxiliary protection function for chemical liver damage | |
| CN110559419A (en) | traditional Chinese medicine composition for preventing and conditioning hypertension and preparation method thereof | |
| CN102188476B (en) | Composition of effective Chinese medicine components for treating hepatic fibrosis | |
| CN102205095A (en) | Medicinal composition with auxiliary blood sugar reducing effect | |
| CN101647857A (en) | Chinese medicine composition for treating stein-leventhal syndrome and preparation method thereof | |
| CN1327875C (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN107753535B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and application thereof | |
| CN1369307A (en) | Composite Chinese medicine for treating heptic fibrosis and cirrhosis due to hepatitis B and its mfg. method | |
| CN101433595A (en) | Desertliving cistanche alcohol extract as well as preparation method and use thereof | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN102028737A (en) | Drug for treating coronary heart disease | |
| CN102028738A (en) | Medicament for treating coronary heart disease and preparation thereof | |
| CN102631492B (en) | Chinese medicinal composition for improving immunity and resisting fatigue | |
| CN1965897B (en) | Chinese medicinal composition for resisting hepatic fibrosis and method for preparing same | |
| CN100348259C (en) | Medicine composition for raising immunity and its prepn and application | |
| CN108498655A (en) | It is a kind of to be used for clearing heat and detoxicating blue gold oral solution and preparation method thereof | |
| CN102631486B (en) | Health care composition | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN102028741B (en) | Medicament for treating coronary heart disease and extraction thereof | |
| CN102631506B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| CN104208250B (en) | A kind of pharmaceutical composition for the treatment of acquired immune deficiency syndrome (AIDS) | |
| CN102631489B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |